Enveric Biosciences, Inc.
ENVB
$5.90
$0.081.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.26% | 6.15% | 38.27% | 44.63% | 56.26% |
| Total Depreciation and Amortization | -28.16% | -17.75% | -12.37% | -17.28% | -17.98% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -45.25% | -9.18% | -39.01% | -34.73% | -58.94% |
| Change in Net Operating Assets | 143.95% | 195.49% | -280.97% | -142.16% | -405.90% |
| Cash from Operations | 6.09% | 34.66% | 34.93% | 45.18% | 48.34% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.59% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 50.43% | 16.84% | 10.64% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -101.40% | -106.83% | -115.31% | 220.83% | 225.94% |
| Cash from Financing | 18.93% | -8.16% | 2.81% | 671.31% | 707.06% |
| Foreign Exchange rate Adjustments | -194.07% | -728.57% | -137.22% | 153.00% | -159.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 155.93% | 81.76% | 66.78% | 99.70% | 93.18% |